<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41880" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Plasmablastic Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Ruchi</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naha</surname>
            <given-names>Kushal</given-names>
          </name>
          <aff>University of Missouri-Columbia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Desai</surname>
            <given-names>Dhaval S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruchi Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kushal Naha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dhaval Desai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41880.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Plasmablastic lymphoma (PBL) is an uncommon but aggressive subtype of diffuse, large B-cell lymphoma classically seen in association with HIV infection.&#x000a0;Despite significant advances in the field of lymphomas since this subtype was first described&#x000a0;in a case series by Delecluse et al in 1997, PBL continues to pose challenges with diagnosis and management.&#x000a0;The primary organs involved are the gastrointestinal system, lymph nodes, oral mucosa, and sometimes the skin. Patients usually present with extranodal masses involving the oral cavity or the gastrointestinal tract. Nodal disease without extranodal involvement is rare.</p>
        <p>PBL is diagnosed primarily through histologic evaluation with or without genetics and immunophenotyping. However, diagnosing PBL is difficult due to&#x000a0;overlapping features with plasmablastic myeloma and other high-grade lymphomas with plasmablastic morphology. Chemotherapy remains the cornerstone of the management of PBL and requires a multidisciplinary approach incorporating medical oncology and infectious disease experts. At the same time, PBL has an aggressive and relapsing course, which results in poor outcomes despite the institution of multi-drug intensive chemotherapy regimens and autologous stem cell transplantation.&#x000a0;Optimal treatment strategies remain unclear partly because of the relative rarity of this disease.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence when managing plasmablastic lymphoma, equipping them with updated knowledge, skills, and strategies for timely identification, effective interventions, and improved care coordination, leading to better patient outcomes and reduced morbidity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess the pathophysiology of plasmablastic lymphoma.</p></list-item><list-item><p>Identify the histopathologic findings of plasmablastic lymphoma.</p></list-item><list-item><p>Select the appropriate evaluation methods to diagnose a patient with plasmablastic lymphoma.</p></list-item><list-item><p>Implement modalities to improve care coordination among interprofessional team members to improve outcomes for patients affected by plasmablastic lymphoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41880&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41880">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41880.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Plasmablastic lymphoma (PBL) is an uncommon but aggressive subtype of diffuse, large B-cell lymphoma.&#x000a0;Despite significant advances in the field of lymphomas since this subtype was first described&#x000a0;in a case series by Delecluse et al in 1997, PBL continues to pose challenges with diagnosis and management.<xref ref-type="bibr" rid="article-41880.r1">[1]</xref> Patients usually present with extranodal masses involving the oral cavity or the gastrointestinal tract. Nodal disease without extranodal involvement is rare.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref>&#x000a0;</p>
        <p>PBL is diagnosed primarily through histologic evaluation with or without genetics and immunophenotyping. However, diagnosing PBL is difficult due to&#x000a0;overlapping features with plasmablastic myeloma and other high-grade lymphomas with plasmablastic morphology. Chemotherapy remains the cornerstone of the management of PBL and requires a multidisciplinary approach incorporating medical oncology and infectious disease experts. At the same time, PBL has an aggressive and relapsing course, which results in poor outcomes despite the institution of multi-drug intensive chemotherapy regimens and autologous stem cell transplantation.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref> These challenges are compounded by the rarity of this condition and the lack of large prospective trials to determine optimal management.&#x000a0;</p>
      </sec>
      <sec id="article-41880.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>While the&#x000a0;exact etiology of this disease remains unknown, there&#x000a0;is abundant clinical data&#x000a0;linking PBL with certain chronic viral infections. For instance, there is a strong association between PBL and HIV infection. In the seminal case series by Delecluse, 15 of the 16 patients described were HIV positive.<xref ref-type="bibr" rid="article-41880.r1">[1]</xref> This&#x000a0;association has been reinforced by subsequent studies, which estimate that nearly two-thirds of cases were HIV positive.<xref ref-type="bibr" rid="article-41880.r4">[4]</xref>&#x000a0;Furthermore, PBL has been described in other immunosuppressed but HIV-negative individuals, including those who have undergone solid organ or bone marrow transplantation or with underlying autoimmune disorders.<xref ref-type="bibr" rid="article-41880.r5">[5]</xref>&#x000a0;PBL is also strongly associated with Epstein-Barr virus<italic toggle="yes">&#x000a0;(</italic>EBV) coinfection.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref>&#x000a0;Several case series support an association between PBL and HHV-8 infection.<xref ref-type="bibr" rid="article-41880.r6">[6]</xref><xref ref-type="bibr" rid="article-41880.r7">[7]</xref></p>
      </sec>
      <sec id="article-41880.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The actual incidence of HIV-positive and HIV-negative PBL&#x000a0;remains unknown.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref>&#x000a0;However, studies have estimated that PBL comprises about 2% of all HIV-related lymphoma cases.<xref ref-type="bibr" rid="article-41880.r8">[8]</xref>&#x000a0;Conversely, a large US-based&#x000a0;case series found that 69% of patients with PBL were HIV positive, confirming the bidirectional association between these conditions.<xref ref-type="bibr" rid="article-41880.r4">[4]</xref>&#x000a0;Interestingly, there appears to be a male predominance in the HIV-positive population,&#x000a0;while the HIV-negative population has a female predominance.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref><xref ref-type="bibr" rid="article-41880.r2">[2]</xref>&#x000a0;Male predominance is also seen in posttransplant PBL and pediatric PBL.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref>&#x000a0;It should be noted that pediatric PBL is rare and predominantly seen in the setting of HIV infection.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref><xref ref-type="bibr" rid="article-41880.r9">[9]</xref><xref ref-type="bibr" rid="article-41880.r10">[10]</xref>&#x000a0;The median age of diagnosis is 42 years in HIV-positive&#x000a0;individuals and 55 years in the&#x000a0;HIV-negative&#x000a0;population. The poor prognosis of this lymphoma is reflected in the median survival of 6 to 11 months.<xref ref-type="bibr" rid="article-41880.r11">[11]</xref></p>
      </sec>
      <sec id="article-41880.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of PBL is incompletely understood, but the plasmablast is believed&#x000a0;to be the cell of origin. The plasmablast is an activated B cell that has undergone somatic hypermutation and class-switching recombination but has not yet become a mature plasma cell. Plasmablasts are a common&#x000a0;histopathologic finding seen in reactive lymph nodes in individuals with HIV and EBV infection. These cells are normally tightly regulated by proapoptotic signals and differentiation-promoting transcription factors. EBV-derived antigens can disrupt this process by protecting B cells from Fas-mediated and B-cell receptor (BCR) mediated apoptosis.<xref ref-type="bibr" rid="article-41880.r12">[12]</xref><xref ref-type="bibr" rid="article-41880.r13">[13]</xref>&#x000a0;Another important component in the pathophysiology of this disease is the MYC oncogene.&#x000a0;Rearrangements of the MYC gene leading to&#x000a0;amplification can be seen in up to 45% of patients with PBL.<xref ref-type="bibr" rid="article-41880.r14">[14]</xref>&#x000a0;MYC overexpression allows B cells to overcome negative regulators such as BCL6 and BLIMP1 and develop into plasmablasts but simultaneously blocks further differentiation into mature plasma cells by downregulating PAX5.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref>&#x000a0;Finally, PBL is also associated with mutations and deletions of the tumor suppression gene TP53 and mutations in the regulatory JAK-STAT pathway,&#x000a0;which likely contribute to the pathophysiology of the disease.<xref ref-type="bibr" rid="article-41880.r15">[15]</xref><xref ref-type="bibr" rid="article-41880.r16">[16]</xref></p>
      </sec>
      <sec id="article-41880.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Plasmablastic lymphoma is characterized by histopathologic features that overlap with other high-grade lymphomas and myeloma. This appearance can be challenging for the pathologist and can be misdiagnosed if a careful workup is not performed. The typical appearance of PBL is that of sheets of large cells with an immunoblastic appearance that effaces the normal tissue architecture. These cells have moderately abundant cytoplasm and central oval nuclei with prominent nucleoli. They can also exhibit a "starry sky pattern" with tingible body macrophages and mitotic figures. Extranodal PBL often demonstrates a more mature plasmacytic appearance with basophilic cytoplasm, perinuclear hof, and an eccentric nucleus that can closely mimic myeloma.<xref ref-type="bibr" rid="article-41880.r17">[17]</xref>&#x000a0;</p>
        <p>The immunophenotype for plasmablastic lymphoma is also similar to that&#x000a0;of plasma cell neoplasms with positive immunohistochemical (IHC) staining for CD79a, IRF-4/MUM-1, CD38, and CD138. Unlike other B-cell lymphomas, PBL is usually negative for CD19, CD20, and PAX-5 but may be weakly positive for CD45. Therefore,&#x000a0;immunophenotyping can also aid in the diagnostic evaluation of PBL.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref>&#x000a0;PBL can also express T-cell markers CD2 or CD4 in a few cases. MYC overexpression is seen in about half of all cases. The Ki-67 proliferation index is&#x000a0;invariably high and often exceeds 90%.<xref ref-type="bibr" rid="article-41880.r18">[18]</xref>&#x000a0;The cells can also be positive for CD30, which has implications for using brentuximab vedotin.<xref ref-type="bibr" rid="article-41880.r18">[18]</xref><xref ref-type="bibr" rid="article-41880.r19">[19]</xref><xref ref-type="bibr" rid="article-41880.r18">[18]</xref><xref ref-type="bibr" rid="article-41880.r20">[20]</xref>&#x000a0;EBV can be detected by EBV-encoded RNA (EBER) expression in the majority of patients but is widespread in HIV-positive individuals.<xref ref-type="bibr" rid="article-41880.r21">[21]</xref>&#x000a0;BCL2 and BCL6 overexpression is not seen with PBL,&#x000a0;which can help distinguish it from triple hit lymphoma and Burkitt lymphoma, respectively.<xref ref-type="bibr" rid="article-41880.r11">[11]</xref></p>
      </sec>
      <sec id="article-41880.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually present with extranodal masses involving the oral cavity or the gastrointestinal tract. Nodal disease without extranodal involvement is rare.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref> Other extranodal sites include&#x000a0;the genitourinary tract, the central nervous system, the lungs, the liver, bones, nasal cavities, and orbits. Most patients present with advanced disease in stage III or IV. Bone marrow involvement is common, with estimates ranging from 27% to 40% of HIV-positive individuals&#x000a0;and 25% of HIV-negative individuals.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref><xref ref-type="bibr" rid="article-41880.r22">[22]</xref><xref ref-type="bibr" rid="article-41880.r23">[23]</xref></p>
      </sec>
      <sec id="article-41880.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>PBL is diagnosed primarily through histologic evaluation with or without genetics and immunophenotyping. PBL is characterized by histopathologic features that overlap with other high-grade lymphomas and myelomas. Therefore, additional diagnostic testing may be necessary for diagnostic confirmation of PBL.&#x000a0;Immunophenotyping can aid in diagnosing PBL as staining can help differentiate this condition from other plasma cell neoplasms.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref>&#x000a0;Genetic analysis through fluorescence in-situ hybridization (FISH) analysis identifying a mutation of the&#x000a0;<italic toggle="yes">MYC</italic>&#x000a0;locus at 8q24 also supports a PBL diagnosis.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref>&#x000a0;(Refer to the <bold>Histopathology</bold>&#x000a0;section for more information on the histologic findings of Plasmablastic Lymphoma).</p>
        <p>Evaluation should be performed as with other high-grade lymphomas. Additional laboratory tests that should be performed include a complete blood count (CBC), which often shows anemia. A complete metabolic panel (CMP), lactate dehydrogenase (LDH), and uric acid should be performed to&#x000a0;screen for possible tumor lysis syndrome. Hepatitis viral panel, HIV testing, and EBV RNA testing should be checked.&#x000a0;Bone marrow biopsy should be performed to evaluate&#x000a0;for bone marrow involvement. PET CT scan can be performed to determine anatomic spread and stage.</p>
      </sec>
      <sec id="article-41880.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Chemotherapy remains the cornerstone of the management of PBL and requires a multidisciplinary approach incorporating medical oncology and infectious disease experts. Surgery has no role in the treatment of PBL as with other aggressive lymphomas. Radiation therapy is restricted to consolidation in patients who are responding to systemic chemotherapy.&#x000a0;</p>
        <p>Because of PBL's rarity, there is no consensus regarding systemic therapy; however, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) are commonly used. There is limited evidence to support a preferred chemotherapy regimen.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref> Dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) are preferred in national guidelines.<xref ref-type="bibr" rid="article-41880.r2">[2]</xref> Chemotherapy usually involves 6 to 8 cycles combined with intrathecal chemotherapy in selected cases.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref> Patients who enter remission after induction chemotherapy should also be considered for consolidation with an autologous stem cell transplant.<xref ref-type="bibr" rid="article-41880.r24">[24]</xref> Patients with HIV should begin or continue their anti-retroviral therapy under the direction of an infectious disease specialist.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref></p>
      </sec>
      <sec id="article-41880.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The following conditions, with their characteristic immunophenotypic and cytogenetic features, should be considered in the differential of PBL:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Plasmablastic myeloma</bold>: positive plasma cell markers including CD38, CD138, and IRF4/MUM1, presence of monoclonal serum immunoglobulin, elevated serum free light chains, renal dysfunction, lytic bone lesions</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Extraosseous plasmacytoma with plasmablastic morphology</bold>: positive plasma cell markers including CD38, CD138, and IRF4/MUM1,&#x000a0;negative for MYC rearrangement, negative EBER</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anaplastic large cell lymphoma kinase (ALK) positive large B cell lymphoma</bold>: positive plasma cell markers including CD38, CD138, and IRF4/MUM1, positive ALK by immunohistochemistry, presence of&#x000a0;t(2;17) or t(2;5)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Extracavitary primary effusion lymphoma</bold>: positive&#x000a0;pan B cell markers, including CD19, CD20, and PAX5, positive for HHV8</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>HHV8 positive diffuse large B cell lymphoma</bold>: positive for IRF4/MUM1, positive for HHV8, negative EBER</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Immunoblastic diffuse large B cell lymphoma</bold>:&#x000a0;positive&#x000a0;pan B&#x000a0;cell markers including CD19, CD20, and&#x000a0;PAX5,&#x000a0;negative for plasma cell markers, EBER may be positive, MYC rearrangements occasionally present</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41880.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>There is no role for surgery&#x000a0;in the management of&#x000a0;PBL. Surgery&#x000a0;is typically not recommended for any form of lymphoma.</p>
      </sec>
      <sec id="article-41880.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation therapy in PBL is limited to case reports and single-institution studies.<xref ref-type="bibr" rid="article-41880.r25">[25]</xref>&#x000a0;Radiation therapy can be used in the refractory setting but is seldom used in the up-front treatment of PBL.<xref ref-type="bibr" rid="article-41880.r26">[26]</xref></p>
      </sec>
      <sec id="article-41880.s13" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Several ongoing trials are pertinent to PBL. These are listed below, along with the phase and current status.</p>
        <list list-type="bullet">
          <list-item>
            <p>Belantamab mafodotin in plasmablastic lymphoma and ALK+ large B-cell lymphoma (NCT04676360, phase 2, recruiting)</p>
          </list-item>
          <list-item>
            <p>Pomalidomide and dose-adjusted EPOCH with and without rituximab for HIV-associated lymphomas (NCT05389423, phase 1, recruiting)</p>
          </list-item>
          <list-item>
            <p>A study of daratumumab and dose-adjusted EPOCH in plasmablastic lymphoma (NCT04139304, phase 1, recruiting)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41880.s14" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>The relative rarity of this lymphoma subtype has meant that robust prospective evidence is not available. However, retrospective studies support the use of aggressive multi-drug chemotherapy regimens similar to other high-grade lymphomas. Although&#x000a0;widely used&#x000a0;in&#x000a0;other large cell lymphomas, the CHOP regimen (ie, cyclophosphamide, doxorubicin, vincristine, and prednisone) is considered inadequate in patients with PBL and therefore is not recommended.<xref ref-type="bibr" rid="article-41880.r3">[3]</xref>&#x000a0;Instead, current guidelines, including those published by the National Comprehensive Cancer Network (NCCN), recommend the use of dose-adjusted EPOCH (ie, etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone).<xref ref-type="bibr" rid="article-41880.r2">[2]</xref> Other regimens that have been suggested include cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) and hyperfractionated cyclophosphamide, vincristine, and doxorubicin (hyper-CVAD), and dexamethasone alternating with methotrexate and cytarabine. Few studies compare these regimens, but at least one&#x000a0;study showed superior overall survival with EPOCH compared to CHOP.<xref ref-type="bibr" rid="article-41880.r27">[27]</xref>&#x000a0;Another emerging regimen combining bortezomib with EPOCH has shown promising results in smaller studies but awaits confirmation from large-scale studies.<xref ref-type="bibr" rid="article-41880.r28">[28]</xref><xref ref-type="bibr" rid="article-41880.r29">[29]</xref></p>
        <p>The role&#x000a0;of intrathecal therapy for primary prophylaxis against central nervous system involvement is uncertain in patients with PBL because of the lack of evidence. However, given the adverse features, including a high proliferation rate, frequent extranodal involvement, association with HIV infection, and presence of MYC rearrangements, considering intrathecal therapy in most patients with PBL is reasonable.</p>
        <p>Autologous stem cell transplantation can be considered as consolidation in patients who are considered fit for such procedures as PBL tends to relapse after induction chemotherapy. However, the evidence to support this approach is limited.<xref ref-type="bibr" rid="article-41880.r30">[30]</xref><xref ref-type="bibr" rid="article-41880.r24">[24]</xref>&#x000a0;The relationship between antiretroviral therapy and outcomes of PBL in HIV-positive individuals remains unclear. Two studies showed improved survival with antiretroviral therapy,&#x000a0;but another did not.<xref ref-type="bibr" rid="article-41880.r31">[31]</xref><xref ref-type="bibr" rid="article-41880.r32">[32]</xref><xref ref-type="bibr" rid="article-41880.r33">[33]</xref></p>
      </sec>
      <sec id="article-41880.s15" sec-type="Staging">
        <title>Staging</title>
        <p>The Ann Arbor staging system is used for staging PBL, similar to other lymphomas.<xref ref-type="bibr" rid="article-41880.r34">[34]</xref>&#x000a0;See StatPearls' companion topic, "Lymphoma," for information on this staging system.</p>
      </sec>
      <sec id="article-41880.s16" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Plasmablastic lymphoma carries a dismal prognosis. Untreated PBL is associated with a median survival of 3 months in HIV-positive individuals and 4 months in HIV-negative individuals.<xref ref-type="bibr" rid="article-41880.r4">[4]</xref>&#x000a0;Treatment with chemotherapy improves survival with median numbers of 10 months, 11 months, and 7 months in patients with HIV-positive, HIV-negative, and post-transplant PBL, respectively.<xref ref-type="bibr" rid="article-41880.r21">[21]</xref>&#x000a0;More recent data using dose-adjusted EPOCH showed 2-year survival rates of 47.4%, reflecting improving outcomes with aggressive chemotherapy regimens.<xref ref-type="bibr" rid="article-41880.r27">[27]</xref> Nevertheless, these numbers reflect the poor prognosis of this disease and the urgent need for more effective therapy.</p>
      </sec>
      <sec id="article-41880.s17" sec-type="Complications">
        <title>Complications</title>
        <p>While receiving chemotherapy, these patients&#x000a0;are at&#x000a0;increased risk of developing complications such as immunosuppression, cytopenias, neutropenic fever, alopecia, infertility, neuropathy, and gastrointestinal toxicities such as nausea, vomiting, and diarrhea. These complications typically resolve after the completion of chemotherapy. Growth factor support with pegfilgrastim is often used to mitigate infectious complications.</p>
      </sec>
      <sec id="article-41880.s18" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Patients undergoing chemotherapy treatment might benefit from a rehabilitation program focused on physical and occupational therapy to stay active while undergoing treatment.</p>
      </sec>
      <sec id="article-41880.s19" sec-type="Consultations">
        <title>Consultations</title>
        <p>Radiation oncology may be consulted to consider consolidative radiation in selected patients with PBL. Palliative care specialists should also be consulted early on during the treatment of PBL. Studies have shown that involving palliative care&#x000a0;soon&#x000a0;improves the quality of life in most cancer patients.<xref ref-type="bibr" rid="article-41880.r35">[35]</xref>&#x000a0;Infectious disease specialists must be consulted for&#x000a0;antiretroviral therapy&#x000a0;in HIV-positive patients with PBL, as well as for assistance with the management of infectious complications of chemotherapy.</p>
      </sec>
      <sec id="article-41880.s20" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the&#x000a0;poor prognosis associated with this diagnosis. Before beginning treatment, they must also be counseled about the possible adverse effects of the intensive chemotherapeutic regimes. Fertility preservation must be offered to all male patients as well as women of childbearing age. Patients should also be educated about the association between this lymphoma subtype and HIV infection and encouraged to undergo testing for HIV so that they can be offered appropriate antiretroviral therapy. Patients should be encouraged to receive vaccinations for influenza and vaccinations and boosters for COVID-19 in a timely fashion because of the increased risk of severe infection with these pathogens after receiving chemotherapy. However, chemotherapy should not be delayed solely for vaccination because of the aggressive nature of this lymphoma.</p>
      </sec>
      <sec id="article-41880.s21" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Plasmablastic lymphoma is a rare and aggressive subtype of lymphoma associated with a poor prognosis, especially when left untreated. Plasmablastic lymphomas are often seen in association with HIV infection and other immunosuppressed states. They are also linked with EBV infection.</p>
        <p>Diagnosing this condition is challenging for pathologists because of its overlapping features with other plasmablastic malignancies. Making an accurate diagnosis is paramount as the treatment strategy for PBL differs from that used for other plasmablastic diseases.&#x000a0;</p>
        <p>Multi-drug systemic chemotherapy is the standard of care for PBL. The relative rarity of this disease has meant that there is limited evidence to support the use of any individual regimen. Still, expert opinion and national guidelines favor the use of dose-adjusted EPOCH.</p>
        <p>Concurrent use of intrathecal chemotherapy should be considered for prophylaxis against central nervous system involvement. Consolidation with autologous stem cell transplantation should be considered in fit patients in first remission with good response to induction chemotherapy.</p>
        <p>Whether timely antiretroviral therapy can prevent this disease is unclear. However, studies suggest that such treatment improves outcomes in HIV-positive individuals with PBL.</p>
      </sec>
      <sec id="article-41880.s22" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Plasmablastic lymphoma poses many challenges in its management. These challenges begin with making the diagnosis and continue during disease management. The medical oncologist typically takes the lead in managing PBL because of the central role of systemic chemotherapy. However, a multidisciplinary approach is essential with&#x000a0;effective communication between the medical oncologist, the pathologist, and the radiologist. The oncologist must also coordinate care with infectious disease physicians managing comorbid HIV infection as well as infectious complications of chemotherapy. Palliative care specialists and social workers must be involved in providing the patient with supportive care needs. The availability of an onco-pharmacist is essential for accurate dosing of chemotherapy, especially when using a complicated regimen like dose-adjusted EPOCH. Finally, well-trained chemotherapy nurses are needed to administer the drugs to the patient safely. To maximize effective communication between these healthcare practitioners, patients should be diagnosed with PBL and discussed at a multidisciplinary tumor board.</p>
      </sec>
      <sec id="article-41880.s23">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41880&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41880">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/plasmablastic-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=41880">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41880/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41880">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41880.s24">
        <title>References</title>
        <ref id="article-41880.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delecluse</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dallenbach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marafioti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmidt-Westhausen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reichart</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.</article-title>
            <source>Blood</source>
            <year>1997</year>
            <month>Feb</month>
            <day>15</day>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>1413</fpage>
            <page-range>1413-20</page-range>
            <pub-id pub-id-type="pmid">9028965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chetty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Verburgh</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Opie</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphoma: An update.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>44 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>54</fpage>
            <page-range>54-63</page-range>
            <pub-id pub-id-type="pmid">36074710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bibas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>The biology and treatment of plasmablastic lymphoma.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Apr</month>
            <day>09</day>
            <volume>125</volume>
            <issue>15</issue>
            <fpage>2323</fpage>
            <page-range>2323-30</page-range>
            <pub-id pub-id-type="pmid">25636338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Stachurski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Butera</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>2047</fpage>
            <page-range>2047-53</page-range>
            <pub-id pub-id-type="pmid">20919850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ochoa-Bayona</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chervenick</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cultrera</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Baz</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kharfan-Dabaja</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Raychaudhuri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sotomayor</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review.</article-title>
            <source>Leuk Res</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1571</fpage>
            <page-range>1571-7</page-range>
            <pub-id pub-id-type="pmid">21752466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cioc</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalmar</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Suster</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baiocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nuovo</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">14707862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deloose</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pals</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>van Noesel</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pals</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.</article-title>
            <source>Leukemia</source>
            <year>2005</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>851</fpage>
            <page-range>851-5</page-range>
            <pub-id pub-id-type="pmid">15744337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carbone</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment.</article-title>
            <source>Hum Pathol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>392</fpage>
            <page-range>392-404</page-range>
            <pub-id pub-id-type="pmid">12055673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pather</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacKinnon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Padayachee</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphoma in pediatric patients: clinicopathologic study of three cases.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-4</page-range>
            <pub-id pub-id-type="pmid">23036261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kriel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pillay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2020</year>
            <month>May</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>e219</fpage>
            <page-range>e219-e227</page-range>
            <pub-id pub-id-type="pmid">32332383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimm</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>O'Malley</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>38</volume>
            <fpage>6</fpage>
            <page-range>6-10</page-range>
            <pub-id pub-id-type="pmid">30380402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kieser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hammerschmidt</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.</article-title>
            <source>EMBO J</source>
            <year>1998</year>
            <month>Mar</month>
            <day>16</day>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1700</fpage>
            <page-range>1700-9</page-range>
            <pub-id pub-id-type="pmid">9501091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bultema</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longnecker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swanson-Mungerson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.</article-title>
            <source>Oncogene</source>
            <year>2009</year>
            <month>Mar</month>
            <day>19</day>
            <volume>28</volume>
            <issue>11</issue>
            <fpage>1471</fpage>
            <page-range>1471-6</page-range>
            <pub-id pub-id-type="pmid">19182823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.</article-title>
            <source>Histopathology</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-211</page-range>
            <pub-id pub-id-type="pmid">31348551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duval</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brennetot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poirel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buhard</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aubry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gabarre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Capello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Canioni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bordessoule</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feuillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delfau</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ferlicot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eclache</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Prevot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guettier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lefevre</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Adotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hamelin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The mutator pathway is a feature of immunodeficiency-related lymphomas.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2004</year>
            <month>Apr</month>
            <day>06</day>
            <volume>101</volume>
            <issue>14</issue>
            <fpage>5002</fpage>
            <page-range>5002-7</page-range>
            <pub-id pub-id-type="pmid">15047891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Filip</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Engelbrecht</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lalloo</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perner</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rabadan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Willem</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.</article-title>
            <source>Blood Cancer Discov</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-125</page-range>
            <pub-id pub-id-type="pmid">33225311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Udden</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cho-Vega</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Finch</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Vilchez</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jorgensen</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.</article-title>
            <source>Mod Pathol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-15</page-range>
            <pub-id pub-id-type="pmid">15578069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harmon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>140</volume>
            <issue>10</issue>
            <fpage>1074</fpage>
            <page-range>1074-8</page-range>
            <pub-id pub-id-type="pmid">27684979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <article-title>HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients: Erratum.</article-title>
            <source>AIDS</source>
            <year>2020</year>
            <month>Nov</month>
            <day>15</day>
            <volume>34</volume>
            <issue>14</issue>
            <fpage>2159</fpage>
            <pub-id pub-id-type="pmid">33105173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-74</page-range>
            <pub-id pub-id-type="pmid">31725418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morscio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dierickx</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nijs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verhoef</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bittoun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vanoeteren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wlodarska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sagaert</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tousseyn</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>875</fpage>
            <page-range>875-86</page-range>
            <pub-id pub-id-type="pmid">24832164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montes-Moreno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martinez-Magunacelaya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zecchini-Barrese</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Villambros&#x000ed;a</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Linares</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ranchal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rodriguez-Pinilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Batlle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cereceda-Company</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Revert-Arce</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Almaraz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piris</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.</article-title>
            <source>Mod Pathol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">27687004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perner</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mayne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiggill</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use.</article-title>
            <source>HIV Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>225</fpage>
            <page-range>225-230</page-range>
            <pub-id pub-id-type="pmid">33022825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Malki</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic cell transplantation for plasmablastic lymphoma: a review.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>1877</fpage>
            <page-range>1877-84</page-range>
            <pub-id pub-id-type="pmid">24946718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinnix</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Costelloe</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wogan</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Milgrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turturro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Romaguera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fanale</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagemeister</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qazilbash</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nieto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hosing</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rohren</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>122</fpage>
            <page-range>122-8</page-range>
            <pub-id pub-id-type="pmid">26795083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases.</article-title>
            <source>Blood Res</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-56</page-range>
            <pub-id pub-id-type="pmid">32269975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makady</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Ramzy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ghaly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abdel-Malek</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Shohdy</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>e255</fpage>
            <page-range>e255-e263</page-range>
            <pub-id pub-id-type="pmid">33419717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dittus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ellsworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>2121</fpage>
            <page-range>2121-2127</page-range>
            <pub-id pub-id-type="pmid">29303024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Guerrero-Garcia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tchernonog</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ninkovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cwynarski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dierickx</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tousseyn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lansigan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Linnik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mogollon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Olszewski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reagan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fedele</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grigoriadis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bibas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>184</volume>
            <issue>4</issue>
            <fpage>679</fpage>
            <page-range>679-682</page-range>
            <pub-id pub-id-type="pmid">29527667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cattaneo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Finel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McQuaker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dreger</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1146</fpage>
            <page-range>1146-7</page-range>
            <pub-id pub-id-type="pmid">25783635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cattaneo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ungari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castelnuovo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fisogni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Petull&#x000e0;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Facchetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>267</fpage>
            <page-range>267-9</page-range>
            <pub-id pub-id-type="pmid">24712980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Stachurski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Butera</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.</article-title>
            <source>Oncologist</source>
            <year>2010</year>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-9</page-range>
            <pub-id pub-id-type="pmid">20167839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Furman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beltr&#x000e1;n</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Bibas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>D&#x000ed;ez-Mart&#x000ed;n</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nanaji</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Seegmiller</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>118</volume>
            <issue>21</issue>
            <fpage>5270</fpage>
            <page-range>5270-7</page-range>
            <pub-id pub-id-type="pmid">22510767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <collab>PDQ Adult Treatment Editorial Board</collab>
            <chapter-title>Hodgkin Lymphoma Treatment (PDQ&#x000ae;): Health Professional Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>10</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">26389473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41880.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hui</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hannon</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruera</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>356</fpage>
            <page-range>356-376</page-range>
            <pub-id pub-id-type="pmid">30277572</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
